<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: The receptor for B-cell-activating factor belonging to the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor family (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) have been established as binding molecules to BAFF </plain></SENT>
<SENT sid="1" pm="."><plain>The aim of this study was to determine the pathological diagnostic roles and clinical significance of these BAFF-binding receptors in B-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: Expression of BAFF-R and TACI was examined immunohistochemically in reactive lymphoid tissues and B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> including diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL), mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), marginal zone B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZBCL</z:e>) and plasma cell <z:mp ids='MP_0009440'>myeloma</z:mp> (PCM) </plain></SENT>
<SENT sid="3" pm="."><plain>In reactive tissues BAFF-R was expressed exclusively in the cells of the mantle zone and within the germinal centres (GCs), whereas TACI appeared positive in the scattered cells in extrafollicular areas </plain></SENT>
<SENT sid="4" pm="."><plain>There were variable patterns of expression of BAFF-R and TACI amongst the different types of B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> and FL: BAFF-R+TACI-; PCM: BAFF-R-TACI+; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZBCL</z:e>: variable expression) </plain></SENT>
<SENT sid="5" pm="."><plain>Reverse transcriptase-polymerase chain reaction studies supported these results </plain></SENT>
<SENT sid="6" pm="."><plain>The overall survival of the BAFF-R+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> group was significantly better than that of the BAFF-R- group </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: These results indicate that the assessment of expression of BAFF-binding receptors <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">aids</z:e> subclassification and prognostication of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
</text></document>